Joseph P Broderick1, Olvert A Berkhemer1, Yuko Y Palesch1, Diederik W J Dippel1, Lydia D Foster1, Yvo B W E M Roos1, Aad van der Lugt1, Thomas A Tomsick1, Charles B L M Majoie1, Wim H van Zwam1, Andrew M Demchuk1, Robert J van Oostenbrugge1, Pooja Khatri1, Hester F Lingsma1, Michael D Hill1, Bob Roozenbeek1, Edward C Jauch1, Tudor G Jovin1, Bernard Yan1, Rüdiger von Kummer1, Carlos A Molina1, Mayank Goyal1, Wouter J Schonewille1, Mikael Mazighi1, Stefan T Engelter1, Craig S Anderson1, Judith Spilker1, Janice Carrozzella1, Karla J Ryckborst1, L Scott Janis1, Kit N Simpson1. 1. From the Departments of Neurology and Rehabilitation Medicine and Radiology, University of Cincinnati Neuroscience Institute, University of Cincinnati Academic Health Center, Cincinnati, OH (J.P.B., P.K., J.S., J.C., T.A.T.); Division of Emergency Medicine (E.C.J.), Department of Public Health Sciences (Y.Y.P., L.D.F.), and Department of Healthcare Management and Leadership (K.N.S.), Medical University of South Carolina, Charleston; Calgary Stroke Program, Seaman Family MR Research Centre, Departments of Clinical Neurosciences and Radiology, Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada (A.M.D., M.D.H., M.G., K.J.R.); the Stroke Institute, University of Pittsburgh Medical Center, PA (T.G.J.); Melbourne Brain Centre, Royal Melbourne Hospital, University of Melbourne, Melbourne, Victoria, Australia (B.Y.); Department of Neuroradiology, Dresden University Stroke Center, University Hospital, Dresden, Germany (R.v.K.); Neurovascular Unit, Department of Neurology, Hospital Universitari Vall d'Hebron, Barcelona, Spain (C.A.M.); Department of Neurology, University Medical Center Utrecht and the Rudolph Magnus Institute of Neurosciences, Utrecht, the Netherlands (W.J.S.); St. Antonius Hospital, Nieuwegein, the Netherlands (W.J.S.); Department of Neurology and Stroke Center, Lariboisière Hospital, Paris, France (M.M.); Department of Neurology, Basel University Hospital, Basel, Switzerland (S.T.E.); the George Institute for Global Health, Royal Prince Alfred Hospital, University of Sydney, Sydney (C.S.A.); and the National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD (L.S.J.); the Department of Radiology (O.A.B., C.B.L.M.M.) and Neurology (Y.B.W.E.M.R.), Academic Medical Center, Amsterdam, the Netherlands; Department of Neurology (D.W.J.D., B.R.), Radiology (A.v.d.L.), and Public Health (H.F.L.), Erasmus MC University Medical Center, Rotterdam, Netherlands; and Department of Radiology (W.H.v.Z.) and N
Abstract
BACKGROUND AND PURPOSE: We assessed the effect of endovascular treatment in acute ischemic stroke patients with severe neurological deficit (National Institutes of Health Stroke Scale score, ≥20) after a prespecified analysis plan. METHODS: The pooled analysis of the Interventional Management of Stroke III (IMS III) and Multicenter Randomized Clinical Trial of Endovascular Therapy for Acute Ischemic Stroke in the Netherlands (MR CLEAN) trials included participants with an National Institutes of Health Stroke Scale score of ≥20 before intravenous tissue-type plasminogen activator (tPA) treatment (IMS III) or randomization (MR CLEAN) who were treated with intravenous tPA ≤3 hours of stroke onset. Our hypothesis was that participants with severe stroke randomized to endovascular therapy after intravenous tPA would have improved 90-day outcome (distribution of modified Rankin Scale scores), when compared with those who received intravenous tPA alone. RESULTS: Among 342 participants in the pooled analysis (194 from IMS III and 148 from MR CLEAN), an ordinal logistic regression model showed that the endovascular group had superior 90-day outcome compared with the intravenous tPA group (adjusted odds ratio, 1.78; 95% confidence interval, 1.20-2.66). In the logistic regression model of the dichotomous outcome (modified Rankin Scale score, 0-2, or functional independence), the endovascular group had superior outcomes (adjusted odds ratio, 1.97; 95% confidence interval, 1.09-3.56). Functional independence (modified Rankin Scale score, ≤2) at 90 days was 25% in the endovascular group when compared with 14% in the intravenous tPA group. CONCLUSIONS:Endovascular therapy after intravenous tPA within 3 hours of symptom onset improves functional outcome at 90 days after severe ischemic stroke. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00359424 (IMS III) and ISRCTN10888758 (MR CLEAN).
RCT Entities:
BACKGROUND AND PURPOSE: We assessed the effect of endovascular treatment in acute ischemic strokepatients with severe neurological deficit (National Institutes of Health Stroke Scale score, ≥20) after a prespecified analysis plan. METHODS: The pooled analysis of the Interventional Management of Stroke III (IMS III) and Multicenter Randomized Clinical Trial of Endovascular Therapy for Acute Ischemic Stroke in the Netherlands (MR CLEAN) trials included participants with an National Institutes of Health Stroke Scale score of ≥20 before intravenous tissue-type plasminogen activator (tPA) treatment (IMS III) or randomization (MR CLEAN) who were treated with intravenous tPA ≤3 hours of stroke onset. Our hypothesis was that participants with severe stroke randomized to endovascular therapy after intravenous tPA would have improved 90-day outcome (distribution of modified Rankin Scale scores), when compared with those who received intravenous tPA alone. RESULTS: Among 342 participants in the pooled analysis (194 from IMS III and 148 from MR CLEAN), an ordinal logistic regression model showed that the endovascular group had superior 90-day outcome compared with the intravenous tPA group (adjusted odds ratio, 1.78; 95% confidence interval, 1.20-2.66). In the logistic regression model of the dichotomous outcome (modified Rankin Scale score, 0-2, or functional independence), the endovascular group had superior outcomes (adjusted odds ratio, 1.97; 95% confidence interval, 1.09-3.56). Functional independence (modified Rankin Scale score, ≤2) at 90 days was 25% in the endovascular group when compared with 14% in the intravenous tPA group. CONCLUSIONS: Endovascular therapy after intravenous tPA within 3 hours of symptom onset improves functional outcome at 90 days after severe ischemic stroke. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00359424 (IMS III) and ISRCTN10888758 (MR CLEAN).
Authors: Yuko Y Palesch; Sharon D Yeatts; Thomas A Tomsick; Lydia D Foster; Andrew M Demchuk; Pooja Khatri; Michael D Hill; Edward C Jauch; Tudor G Jovin; Bernard Yan; Rüdiger von Kummer; Carlos A Molina; Mayank Goyal; Wouter J Schonewille; Mikael Mazighi; Stefan T Engelter; Craig Anderson; Judith Spilker; Janice Carrozzella; Karla J Ryckborst; L Scott Janis; Annie Simpson; Kit N Simpson; Joseph P Broderick Journal: Stroke Date: 2015-04-09 Impact factor: 7.914
Authors: Jeffrey L Saver; Mayank Goyal; Alain Bonafe; Hans-Christoph Diener; Elad I Levy; Vitor M Pereira; Gregory W Albers; Christophe Cognard; David J Cohen; Werner Hacke; Olav Jansen; Tudor G Jovin; Heinrich P Mattle; Raul G Nogueira; Adnan H Siddiqui; Dileep R Yavagal; Blaise W Baxter; Thomas G Devlin; Demetrius K Lopes; Vivek K Reddy; Richard du Mesnil de Rochemont; Oliver C Singer; Reza Jahan Journal: N Engl J Med Date: 2015-04-17 Impact factor: 91.245
Authors: Bruce C V Campbell; Peter J Mitchell; Timothy J Kleinig; Helen M Dewey; Leonid Churilov; Nawaf Yassi; Bernard Yan; Richard J Dowling; Mark W Parsons; Thomas J Oxley; Teddy Y Wu; Mark Brooks; Marion A Simpson; Ferdinand Miteff; Christopher R Levi; Martin Krause; Timothy J Harrington; Kenneth C Faulder; Brendan S Steinfort; Miriam Priglinger; Timothy Ang; Rebecca Scroop; P Alan Barber; Ben McGuinness; Tissa Wijeratne; Thanh G Phan; Winston Chong; Ronil V Chandra; Christopher F Bladin; Monica Badve; Henry Rice; Laetitia de Villiers; Henry Ma; Patricia M Desmond; Geoffrey A Donnan; Stephen M Davis Journal: N Engl J Med Date: 2015-02-11 Impact factor: 91.245
Authors: Mikael Mazighi; Saqib A Chaudhry; Marc Ribo; Pooja Khatri; David Skoloudik; Maxim Mokin; Julien Labreuche; Elena Meseguer; Sharon D Yeatts; Adnan H Siddiqui; Joseph Broderick; Carlos A Molina; Adnan I Qureshi; Pierre Amarenco Journal: Circulation Date: 2013-05-14 Impact factor: 29.690
Authors: Pooja Khatri; Michael D Hill; Yuko Y Palesch; Judith Spilker; Edward C Jauch; Janice A Carrozzella; Andrew M Demchuk; Renee' Martin; Patrick Mauldin; Catherine Dillon; Karla J Ryckborst; Scott Janis; Thomas A Tomsick; Joseph P Broderick Journal: Int J Stroke Date: 2008-05 Impact factor: 5.266
Authors: Joseph P Broderick; Yuko Y Palesch; Andrew M Demchuk; Sharon D Yeatts; Pooja Khatri; Michael D Hill; Edward C Jauch; Tudor G Jovin; Bernard Yan; Frank L Silver; Rüdiger von Kummer; Carlos A Molina; Bart M Demaerschalk; Ronald Budzik; Wayne M Clark; Osama O Zaidat; Tim W Malisch; Mayank Goyal; Wouter J Schonewille; Mikael Mazighi; Stefan T Engelter; Craig Anderson; Judith Spilker; Janice Carrozzella; Karla J Ryckborst; L Scott Janis; Renée H Martin; Lydia D Foster; Thomas A Tomsick Journal: N Engl J Med Date: 2013-02-07 Impact factor: 91.245
Authors: William J Powers; Colin P Derdeyn; José Biller; Christopher S Coffey; Brian L Hoh; Edward C Jauch; Karen C Johnston; S Claiborne Johnston; Alexander A Khalessi; Chelsea S Kidwell; James F Meschia; Bruce Ovbiagele; Dileep R Yavagal Journal: Stroke Date: 2015-06-29 Impact factor: 10.170
Authors: Puck S S Fransen; Debbie Beumer; Olvert A Berkhemer; Lucie A van den Berg; Hester Lingsma; Aad van der Lugt; Wim H van Zwam; Robert J van Oostenbrugge; Yvo B W E M Roos; Charles B Majoie; Diederik W J Dippel Journal: Trials Date: 2014-09-01 Impact factor: 2.279
Authors: Xuanqian Xie; Anna Lambrinos; Brian Chan; Irfan A Dhalla; Timo Krings; Leanne K Casaubon; Cheemun Lum; Nancy Sikich; Aditya Bharatha; Vitor Mendes Pereira; Grant Stotts; Gustavo Saposnik; Christina O'Callaghan; Linda Kelloway; Michael D Hill Journal: CMAJ Open Date: 2016-06-16
Authors: Kais Mnafgui; Lakhdar Ghazouani; Raouf Hajji; Abir Tlili; Fatma Derbali; Francisco Ivan da Silva; Joabe Lima Araújo; Bianca de Oliveira Schinoff; José Fernando Ruggiero Bachega; Antônia Laíres da Silva Santos; Noureddine Allouche Journal: Neurochem Res Date: 2021-05-18 Impact factor: 3.996
Authors: Esmee Venema; Maxim J H L Mulder; Bob Roozenbeek; Joseph P Broderick; Sharon D Yeatts; Pooja Khatri; Olvert A Berkhemer; Bart J Emmer; Yvo B W E M Roos; Charles B L M Majoie; Robert J van Oostenbrugge; Wim H van Zwam; Aad van der Lugt; Ewout W Steyerberg; Diederik W J Dippel; Hester F Lingsma Journal: BMJ Date: 2017-05-03
Authors: Maxim J H L Mulder; Esmee Venema; Bob Roozenbeek; Joseph P Broderick; Sharon D Yeatts; Pooja Khatri; Olvert A Berkhemer; Yvo B W E M Roos; Charles B L M Majoie; Robert J van Oostenbrugge; Wim H van Zwam; Aad van der Lugt; Ewout W Steyerberg; Diederik W J Dippel; Hester F Lingsma Journal: BMJ Open Date: 2017-03-22 Impact factor: 2.692
Authors: Bruce C V Campbell; Michael D Hill; Marta Rubiera; Bijoy K Menon; Andrew Demchuk; Geoffrey A Donnan; Daniel Roy; John Thornton; Laura Dorado; Alain Bonafe; Elad I Levy; Hans-Christoph Diener; María Hernández-Pérez; Vitor Mendes Pereira; Jordi Blasco; Helena Quesada; Jeremy Rempel; Reza Jahan; Stephen M Davis; Bruce C Stouch; Peter J Mitchell; Tudor G Jovin; Jeffrey L Saver; Mayank Goyal Journal: Stroke Date: 2016-03 Impact factor: 7.914